BR112012018132A2 - "marcadores de células - tronco tumorais e uso dos mesmos". - Google Patents
"marcadores de células - tronco tumorais e uso dos mesmos".Info
- Publication number
- BR112012018132A2 BR112012018132A2 BR112012018132A BR112012018132A BR112012018132A2 BR 112012018132 A2 BR112012018132 A2 BR 112012018132A2 BR 112012018132 A BR112012018132 A BR 112012018132A BR 112012018132 A BR112012018132 A BR 112012018132A BR 112012018132 A2 BR112012018132 A2 BR 112012018132A2
- Authority
- BR
- Brazil
- Prior art keywords
- tumor stem
- stem cell
- cell markers
- tumor
- stem cells
- Prior art date
Links
Classifications
-
- G01N33/5756—
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57469—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumor associated glycolinkage, i.e. TAG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29673810P | 2010-01-20 | 2010-01-20 | |
| EP10000527A EP2347769A1 (en) | 2010-01-20 | 2010-01-20 | Cancer stem cell markers and uses thereof |
| PCT/EP2011/000217 WO2011089004A1 (en) | 2010-01-20 | 2011-01-20 | Cancer stem cell markers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012018132A2 true BR112012018132A2 (pt) | 2017-06-20 |
Family
ID=42173400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012018132A BR112012018132A2 (pt) | 2010-01-20 | 2011-01-20 | "marcadores de células - tronco tumorais e uso dos mesmos". |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20120294859A1 (enExample) |
| EP (2) | EP2347769A1 (enExample) |
| JP (2) | JP2013517487A (enExample) |
| CN (1) | CN102753199A (enExample) |
| AU (1) | AU2011208874B2 (enExample) |
| BR (1) | BR112012018132A2 (enExample) |
| CA (1) | CA2786212A1 (enExample) |
| WO (1) | WO2011089004A1 (enExample) |
Families Citing this family (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| DK2318832T3 (da) | 2008-07-15 | 2014-01-20 | Academia Sinica | Glycan-arrays på PTFE-lignende aluminiumcoatede objektglas og relaterede fremgangsmåder |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| WO2012031280A2 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| WO2012039430A1 (ja) * | 2010-09-21 | 2012-03-29 | 株式会社Ｇｐバイオサイエンス | がん幹細胞の単離方法 |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| AU2013306098A1 (en) | 2012-08-18 | 2015-02-12 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| EP2972390B1 (en) | 2013-03-14 | 2017-11-08 | The United States Of America, As Represented By The Sectretary, Department Of Health And Human Services | Hyposialylation disorders |
| WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
| US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
| CN105682666B (zh) | 2013-09-06 | 2021-06-01 | 中央研究院 | 使用醣脂激活人类iNKT细胞 |
| ES2914176T3 (es) | 2013-09-17 | 2022-06-07 | Obi Pharma Inc | Composiciones de una vacuna glucídica para inducir respuestas inmunitarias y usos de las mismas en el tratamiento de cáncer |
| EP3094352B1 (en) | 2014-01-16 | 2020-09-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| WO2015148915A1 (en) | 2014-03-27 | 2015-10-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
| RU2699717C2 (ru) * | 2014-04-18 | 2019-09-09 | Дзе Ресёч Фаундэйшен Фор Дзе Штат Юниверсити Ов Нью-Йорк | Гуманизированные антитела к антигену Томсена-Фриденрайха |
| US10023651B2 (en) | 2014-04-18 | 2018-07-17 | The Research Foundation For The State University Of New York | Humanized anti-TF-antigen antibodies |
| CN103969437B (zh) * | 2014-04-22 | 2017-03-22 | 广州恒泰生物科技有限公司 | 用于卵巢癌早中期快速诊断试剂盒的制备方法 |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| KR20170010003A (ko) | 2014-05-27 | 2017-01-25 | 아카데미아 시니카 | 박테로이드 기원의 푸코시다제 및 이의 사용 방법 |
| IL249188B2 (en) | 2014-05-27 | 2024-03-01 | Academia Sinica | Anti-her2 glycoantibodies and uses thereof |
| KR20170003720A (ko) | 2014-05-27 | 2017-01-09 | 아카데미아 시니카 | 항-ｃｄ20 글리코항체 및 이의 용도 |
| CN106714829A (zh) | 2014-05-28 | 2017-05-24 | 中央研究院 | 抗TNF‑α醣抗体及其用途 |
| CA2960712A1 (en) | 2014-09-08 | 2016-03-17 | Academia Sinica | Human inkt cell activation using glycolipids |
| IL278574B2 (en) | 2014-11-12 | 2024-11-01 | Seagen Inc | Glycan-interacting compounds and methods of use |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| KR102630294B1 (ko) * | 2015-01-24 | 2024-01-26 | 아카데미아 시니카 | 암 마커 및 이를 사용하는 방법 |
| CA2972072A1 (en) | 2015-01-24 | 2016-07-28 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
| WO2016137963A1 (en) | 2015-02-25 | 2016-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sialylation-increasing therapies for diseases associated with oxidative stress |
| KR20180050339A (ko) | 2015-09-04 | 2018-05-14 | 오비아이 파머 인코퍼레이티드 | 글리칸 어레이 및 사용 방법 |
| EP3373969A4 (en) | 2015-11-12 | 2019-08-14 | Siamab Therapeutics, Inc. | GLYCANINTERAGING COMPOUNDS AND METHOD OF USE |
| WO2017100796A1 (en) * | 2015-12-11 | 2017-06-15 | SINACA, Academia | Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers |
| WO2017156192A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
| EP3436482A4 (en) | 2016-03-29 | 2020-03-11 | OBI Pharma, Inc. | ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| JP7544465B2 (ja) | 2016-04-22 | 2024-09-03 | オービーアイ ファーマ，インコーポレイテッド | グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法 |
| KR20190067765A (ko) | 2016-07-27 | 2019-06-17 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료 글리칸 조성물 및 그의 용도 |
| TWI786054B (zh) | 2016-07-29 | 2022-12-11 | 台灣浩鼎生技股份有限公司 | 人類抗體、醫藥組合物、及其方法 |
| TWI764917B (zh) | 2016-08-22 | 2022-05-21 | 醣基生醫股份有限公司 | 抗體、結合片段及使用方法 |
| WO2018094143A1 (en) | 2016-11-17 | 2018-05-24 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
| AU2017360168B2 (en) | 2016-11-18 | 2023-10-12 | Astellas Pharma Inc. | Novel anti-human MUC1 antibody Fab fragment |
| KR20190077103A (ko) | 2016-11-21 | 2019-07-02 | 오비아이 파머 인코퍼레이티드 | 접합된 생물학적 분자, 제약 조성물 및 방법 |
| BR112019018043A2 (pt) | 2017-03-03 | 2020-04-07 | Seattle Genetics Inc | método de tratamento de câncer, e, conjugado de anticorpo-fármaco |
| EP3601357A1 (en) * | 2017-03-29 | 2020-02-05 | Glycotope GmbH | Multispecific antibody constructs binding to muc1 and cd3 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| PE20211001A1 (es) | 2018-02-27 | 2021-06-01 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
| PT110722B (pt) * | 2018-05-03 | 2021-08-17 | Instituto De Patologia E Imunologia Molecular Da Univ Do Porto Ipatimup | Uso de anticorpos para o antigénio thomsen-friedenreich num método e estojo para avaliação de instabilidade de microsatelites |
| US12202908B2 (en) | 2018-05-17 | 2025-01-21 | Astellas Pharma Inc. | Complex having anti-human MUC1 antibody Fab fragment, peptide linker and/or ligand |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| MY206244A (en) | 2018-05-18 | 2024-12-05 | Daiichi Sankyo Co Ltd | Anti-muc1 antibody-drug conjugate |
| US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| GEP20237560B (en) | 2018-07-05 | 2023-10-25 | Incyte Corp | Fused pyrazine derivatives as a2a / a2b inhibitors |
| MX2021004146A (es) | 2018-10-10 | 2021-06-08 | Astellas Pharma Inc | Composicion farmaceutica que contiene complejo de fragmento fab de anticuerpo antihumano con sitio marcado. |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN110161241A (zh) * | 2019-04-30 | 2019-08-23 | 丁晓昆 | 一种快速检测生物组织切片cosmc基因突变试剂盒 |
| IL294437A (en) | 2020-01-03 | 2022-09-01 | Incyte Corp | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| AR120936A1 (es) | 2020-01-03 | 2022-03-30 | Incyte Corp | Anticuerpos anti-cd73 y usos de estos |
| CN113388023A (zh) * | 2020-03-18 | 2021-09-14 | 北京鼎成肽源生物技术有限公司 | 一种输卵管癌靶标抗原、输卵管癌靶标抗原刺激培养的ctl细胞及其应用 |
| US12415864B2 (en) | 2020-06-30 | 2025-09-16 | Pentixapharm Ag | Humanized antibodies against Lewis Y |
| CA3207066A1 (en) | 2020-12-29 | 2022-07-07 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
| JP2024504406A (ja) * | 2021-01-25 | 2024-01-31 | ユニオジェン・オサケユフティオ | 膀胱がんのバイオマーカーとしてのＦＵＣα（１－２）Ｇａｌ糖鎖構造の使用 |
| US20240382590A1 (en) * | 2021-07-16 | 2024-11-21 | Université de Montréal | Novel tumor-specific antigens for cancer stem cells and uses thereof |
| CN113804531B (zh) * | 2021-09-10 | 2024-02-06 | 北京大学 | 一种细胞高活性染色方法 |
| CN119955728A (zh) * | 2022-08-01 | 2025-05-09 | 首都医科大学附属北京胸科医院 | 恶性表型大细胞肺癌细胞株及其应用 |
| CN116718774A (zh) * | 2023-07-07 | 2023-09-08 | 杭州准星医学科技有限公司 | 一种用于肿瘤体外诊断的试剂盒及其使用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| DE10256900A1 (de) | 2002-11-29 | 2004-06-24 | Nemod Immuntherapie Ag | Tumorspezifische Erkennungsmoleküle |
| PT1654353E (pt) | 2003-08-18 | 2013-08-23 | Glycotope Gmbh | Linhas de células tumorais nm f9 (dsm acc2606) e nm d4 (dsm acc2605), suas utilizações |
| JP4904266B2 (ja) * | 2004-07-26 | 2012-03-28 | ザ リサーチ ファウンデイション オブ ステイト ユニバーシティー オブ ニューヨーク | 抗−ｔｆ−抗原抗体の治療的使用 |
| CA2674269C (en) * | 2006-01-03 | 2018-06-12 | University Of Georgia Research Foundation, Inc. | Three component glycolipopeptides |
| US20110190166A1 (en) * | 2006-05-26 | 2011-08-04 | Susan Wong | Erythroid progenitor cells and methods for producing parvovirus b19 therein |
-
2010
- 2010-01-20 EP EP10000527A patent/EP2347769A1/en not_active Withdrawn
-
2011
- 2011-01-20 AU AU2011208874A patent/AU2011208874B2/en not_active Ceased
- 2011-01-20 CN CN2011800065922A patent/CN102753199A/zh active Pending
- 2011-01-20 BR BR112012018132A patent/BR112012018132A2/pt active Search and Examination
- 2011-01-20 WO PCT/EP2011/000217 patent/WO2011089004A1/en not_active Ceased
- 2011-01-20 EP EP11703580A patent/EP2525832A1/en not_active Withdrawn
- 2011-01-20 CA CA2786212A patent/CA2786212A1/en not_active Abandoned
- 2011-01-20 US US13/574,260 patent/US20120294859A1/en not_active Abandoned
- 2011-01-20 JP JP2012549291A patent/JP2013517487A/ja not_active Ceased
-
2015
- 2015-12-25 JP JP2015253064A patent/JP2016047848A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2347769A1 (en) | 2011-07-27 |
| US20120294859A1 (en) | 2012-11-22 |
| EP2525832A1 (en) | 2012-11-28 |
| WO2011089004A1 (en) | 2011-07-28 |
| CN102753199A (zh) | 2012-10-24 |
| CA2786212A1 (en) | 2011-07-28 |
| JP2013517487A (ja) | 2013-05-16 |
| JP2016047848A (ja) | 2016-04-07 |
| AU2011208874A1 (en) | 2012-08-02 |
| AU2011208874B2 (en) | 2015-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012018132A2 (pt) | "marcadores de células - tronco tumorais e uso dos mesmos". | |
| BR112014015851A2 (pt) | proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17 | |
| EA201590207A1 (ru) | Композиции и способы регуляции car-т-клеток | |
| BR112014026703A2 (pt) | inibidores de dna-pk | |
| BRPI0821145B8 (pt) | uso de um anticorpo anti-nr10 como agente preventivo ou terapêutico para prurido | |
| BRPI0906478B8 (pt) | anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende | |
| BR112016023436A2 (pt) | compostos conjugados compreendendo anticorpos com manipulação de cisteínas | |
| MX350200B (es) | Anticuerpos humanos y conjugados de anticuerpo-farmaco contra cd74. | |
| CO7151488A2 (es) | Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos | |
| BR112012021296A2 (pt) | imunoconjugados e anticorpos de receptor de folato 1 e usos dos mesmos. | |
| MX2015005328A (es) | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. | |
| AR062268A1 (es) | Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos | |
| UY35147A (es) | Anticuerpos anti-ceacam5 y usos de éstos. | |
| ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
| BR112012023010A2 (pt) | "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37" | |
| GT201100011DA (es) | Anticuerpos neutralizantes de citomegalovirus humano y udso de los mismos | |
| MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
| BR112017027498A2 (pt) | anticorpo, ácido nucleico, composto, composição, e, método para tratamento de um paciente com uma doença. | |
| CR20130016A (es) | ANTICUERPOS PEPTIDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| UA116772C2 (uk) | Виділене моноклональне антитіло або його імунологічно-активний фрагмент, що зв'язується з cd47 | |
| BR112012032008A2 (pt) | anticorpos s100a4 e usos terapêuticos do mesmo | |
| AR090884A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
| BR112014029099A2 (pt) | anticorpos anti-egfr e seu uso para inibir ou atenuar crescimento de tumor, bem como composição farmacêutica que o compreende | |
| HK1216850A1 (zh) | 抗ntb-a抗體及相關的組合物和方法 | |
| UA115439C2 (uk) | Гуманізоване антитіло, яке розпізнає альфа-синуклеїн |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: A61K 47/00 (2006.01), C07K 16/30 (2006.01), C07K 1 |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2497 DE 13/11/2018. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |